Physician profile
Devon James Pyykkonen
NPI 1225696404
$4,216.10
in general payments reported to CMS, 2019-2025
20 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $148 · 2021: $62.20 · 2022: $254 · 2023: $1,276 · 2024: $2,035 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.59 |
| Education | $128.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,310.71 | 2023-2025 | |
| Janssen Biotech, INC. | $611.36 | 2022-2024 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $262.57 | 2022-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $259.22 | 2022-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.43 | 2020-2025 | Xifaxan, Plenvu |
| Ardelyx, INC. | $196.00 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $184.52 | 2024 | |
| Ironwood Pharmaceuticals, INC | $173.65 | 2023-2024 | Linzess |
| Pfizer INC. | $157.10 | 2024-2025 | |
| Gilead Sciences, INC. | $155.09 | 2021-2024 | Epclusa |
| Janssen Scientific Affairs, LLC | $137.96 | 2020-2024 | Tremfya |
| Qol Medical, LLC | $126.00 | 2023 | Sucraid |
| Evoke Pharma, INC. | $103.45 | 2023 | Gimoti |
| Sandoz INC. | $87.54 | 2023-2024 | Hyrimoz |
| Exact Sciences Corporation | $86.31 | 2024 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.63 | 2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $40.48 | 2020-2024 | |
| Vivus LLC | $31.01 | 2021-2025 | Qsymia |
| Celltrion USA INC. | $29.23 | 2024 | Zymfentra |
| Organon LLC | $17.84 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Pyykkonen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.